TELESCOPE INNOVATIONS CORP Stock Price, News & Analysis

Telescope Innovations (OTCQB: TELIF) announced expansion of its lithium development infrastructure and technical validations for its proprietary processes on January 27, 2026. The company leased additional lab and scale-up space adjacent to its UBC labs to house reactors and analytical equipment for air-sensitive materials like lithium sulfide, with commissioning as a near-term priority.

Technical milestones include ReCRFT producing battery-grade Li2CO3 that was successfully used by a recycling partner to manufacture a functional battery cell, and DualPure demonstrating a low-temperature route to high-purity Li2S with development funded in part by Standard Lithium.

Telescope (OTCQB:TELIF) outlined a 2026 development pipeline to expand its DirectInject-LC platform into DirectInject-IC (ion chromatography) and DirectInject-ICP (inductively coupled plasma) to broaden real-time analytical capabilities for Self-Driving Labs. The company positions these integrations to enable autonomous, quantitative monitoring across inorganic chemistry, hydrometallurgy, lithium extraction, and energy & battery materials.

Early-adopter deployments and testing are targeted for H2 2026, aiming to extend commercial reach beyond organic chemistry into minerals and industrial process monitoring.

Telescope Innovations (OTCQB: TELIF) provided a strategic update on accelerating commercial adoption of Self-Driving Labs (SDLs) and the rise of Physical AI on January 5, 2026.

Key developments include a successful pharmaceutical SDL deployment for the KPBMA, a multi-year, funded SDL development project with Pfizer, and management saying FY 2025 delivered record sales performance. The release cites industry validation: Gartner named Physical AI a 2026 macro trend, Global X flagged an "Automation Age," and Grand View Research projects the global lab-automation market to reach US $18.39 billion by 2033 (CAGR 9.3%).

The company positions its SDL architecture as a scalable industrial asset for pharmaceuticals, industrial chemistry, agriculture & energy, and long-term space/off-Earth research.

Telescope Innovations (OTCQB: TELIF) authorized equity compensation and a shares-for-debt settlement on December 31, 2025. The company granted up to 250,000 stock options to a consultant at a strike of $0.33 exercisable until Dec 31, 2030 with a four-month-plus-one-day cliff and annual vesting thereafter. It also granted 192,000 RSUs to three directors valued at $48,000 under director fee arrangements with the same vesting schedule.

The CEO, Henry Dubina, agreed to settle $12,000 of fees via issuance of 48,000 common shares at a deemed price of $0.25 per share; those shares carry the statutory four-month hold. The company disclosed this as a related-party transaction and said it will rely on specified MI 61-101 exemptions.

Telescope Innovations (OTCQB: TELIF) reported fiscal 2025 results for the year ended August 31, 2025, with revenues of CAD $5.8M versus $4.4M in FY2024 and an Adjusted EBITDA loss of $402K (FY2024 loss $152K). Expenses rose to CAD $7.3M.

Operational milestones include a multi‑year funded Self‑Driving Lab (SDL) project with Pfizer, record quarterly sales for DirectInject‑LC and expansion into Europe and Asia, production and first sample shipments of battery‑grade lithium sulfide, and planned deployment of the first SDL for pharmaceutical development in Korea in FY2026.

Telescope Innovations (OTCQB: TELIF) completed installation of Korea's first pharmaceutical Self-Driving Lab (SDL) for the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association on December 9, 2025. The SDL was deployed only three weeks after contract signing, demonstrating rapid delivery capability. The project included on-site participation by two-time Chemistry Nobel Prize winner Prof. Barry Sharpless and was enabled by collaboration with the Acceleration Consortium and Canadian–Korean partners. Telescope says the installation will accelerate R&D workflows via automated robotics, inline analytics, and AI, and positions the company to expand SDL adoption across pharmaceutical, industrial chemistry, energy, and agricultural sectors.

Telescope Innovations (OTCQB: TELIF) announced that Korea's Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) has purchased a Self-Driving Lab (SDL) to be installed at a new R&D facility in Seoul within weeks (announcement dated November 17, 2025).

The SDL will form the core of KPBMA's first AI-driven training hub under the Convergence AI Institute for Drug Discovery (CAIID), supporting automation, education, and upskilling across KPBMA's 300 member companies. Telescope said the SDL uses robotics, inline analytics, and AI to run continuous closed-loop experiments that can accelerate iterative R&D and shorten development timelines. Telescope and KPBMA plan a strategic partnership to deploy and promote SDL adoption across Korea and the wider Asian market.

Telescope Innovations (OTCQB: TELIF) received formal and conditional government support totalling up to CAD $3.36M to advance lithium processing technologies on November 4, 2025. NRC IRAP provides advisory services and up to $319,200 for demonstration of ReCRFT™ lithium carbonate crystallization for battery recycling. NRCan CMRDD conditionally approved $3.04M to scale and pilot DualPure™ low-temperature lithium sulphide synthesis for solid-state battery materials. The programs run through Telescope's automated R&D labs to accelerate demonstration and scale-up.

Telescope Innovations (OTCQB: TELIF) announced a debt settlement on October 23, 2025, issuing a total of 689,654 common shares at a deemed price of CAD $0.29 per share.

The issuance settles CAD $100,000 of indebtedness to Jason Hein, CTO and director, via 344,827 shares, and CAD $100,000 of a secured loan via 344,827 shares. The secured loan originally provided CAD $1,200,000, bears 6.95% annual interest and matures on June 1, 2026.

Hein is a related party under MI 61-101; the company relied on exemptions to formal valuation and minority approval. All issued shares carry a statutory hold of four months and one day. Completion is subject to Canadian Securities Exchange and other regulatory approvals.